Teva Respiratory, an affiliate of Teva Pharmaceutical Industries, completed its digital inhaler portfolio today with the launch of two new products: the AirDuo Digihaler and the ArmonAir Digihaler.
Both of the new inhalers are prescription inhalation powders designed to treat people with asthma 12 years and older. The AirDuo can be used to control symptoms of asthma and to prevent symptoms such...
Jerusalem-based Teva Pharmaceuticals announced this week the U.S. launch of its ProAir Digihaler.
The sensor-laden albuterol dispenser requires a prescription, and is indicated for those aged four years or older with reversible obstructive airway diseases such as asthma and COPD, as well as for the prevention of exercise-induced bronchospasm (EIB) among this same group.
The device connects to a...
This morning Teva Pharmaceutical Industries announced that the FDA greenlighted its AirDuo Digihaler, a sensor-enabled inhaler. The product, classified as a maintenance asthma inhaler, has a built-in sensor that sends usage data to a corresponding app on a user's smartphone. This information can also be sent to the user’s provider.
The sensor technology is also able to monitor inspiratory flow...
At MEDinIsrael 2019 this week, a conference in Tel Aviv sponsored by the Israeli Export Institute, Dr. Lena Granovsky, director of analytics and big data at Teva Pharmaceuticals, spoke on and off stage about the work the top Israeli pharma company has been doing in digital health. These topics included the company's recently FDA-cleared smart inhaler ProAir Digihaler, as well as more broad...
Jerusalem-based Teva Pharmaceuticals’ sensor-packed, app-connected digital inhaler has recently received marketing approval from the US FDA, according to a release from the company. The device will first become available next year through a “small number” of healthcare system pilot partnerships, with a full national launch currently planned for 2020.
Teva’s ProAir Digihaler is indicated for the...
Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18.
“This is going to be a completely new industry sector,” Pierre Leurent, CEO of Voluntis, said during the session. “It’s going to have very strong growth in the years to come and it’s going to be a...
BioSensics, a Cambridge, Massachusetts-based developer of wearable health sensors, has received more than $2.5 million in NIH grant funding for its Huntington’s disease (HD) monitoring device.
The device, called HDWear, provides real-time quantitative motor symptom scores that can assist with managing the hereditary neurological disease. These measures usually require in-clinic assessments such...
Ashdod, Israel-based Integrity Applications, makers of noninvasive glucose monitor GlucoTrak, has hired a new chief financial officer, Sami Sassoun. A veteran CFO, Sassoun most recently worked at Bedrock Enterprises, a boutique consulting firm he founded.
"We are very pleased to welcome Sami as our chief financial officer and member of the executive team," Avner Gal, chief executive officer of...
Omada Health has announced five new senior hires, most notably a new chief medical officer, Dr. Paul Chew, who previously served as senior VP and global chief medical officer at Sanofi. The company also announced the hire of Tom Schoenherr as chief commercial officer, a position he previously held at Counsyl.
“For the last five years, we’ve worked to establish Omada Health as a leader in digital...
Verily -- the Alphabet spinoff formerly known as Google Life Sciences -- has launched a new smart spoon that recognizes uncontrollable or unsteady hand movements at all times and automatically compensates, enabling people to eat without spilling.
The robotic device, Liftware Level, is the second offering from Liftware, a company devoted to developing tools to aid those with motor impairments that...
